CHU Limoges

Running trials

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Source

• Recruiting

  Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

  NCT07418827· Source

• Recruiting

  Cohort of Patients With Chronic Myelomonocytic Leukemia

  NCT07512882· Source

• Recruiting

  Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

  NCT07205731· Phase 2· Source

• Recruiting

  Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)

  NCT07295808· Source

• Not yet recruiting

  Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

  NCT06931704· Phase 2· Source

• Recruiting

  Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

  NCT06487273· Source

• Recruiting

  Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

  NCT06487078· Source

• Recruiting

  Epidemiological Data on Mast Cell Pathologies in France

  NCT06186856· Source

• Recruiting

  Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data

  NCT06380192· Source

• Active, not recruiting

  Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

  NCT06557889· Phase 2· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· Source

• Recruiting

  Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

  NCT06427304· Source

• Active, not recruiting

  Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

  NCT06353022· Phase 2· Source

• Recruiting

  An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

  NCT06035120· Source

• Recruiting

  DELTA DESCRIBE: the French Collaborative Project

  NCT05936073· Source

• Recruiting

  PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

  NCT05581121· Phase 3· Source

• Recruiting

  Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

  NCT06083129· Phase 3· Source

• Recruiting

  Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

  NCT06130787· Source

• Recruiting

  Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

  NCT05917405· Phase 2· Source

• Recruiting

  Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy

  NCT05944913· Source

• Recruiting

  Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

  NCT05772559· Source

• Active, not recruiting

  Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

  NCT05825573· Phase 3· Source

• Recruiting

  Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol

  NCT05320263· Source

• Recruiting

  MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

  NCT05691608· Source

• Recruiting

  Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy

  NCT04802135· Source

• Recruiting

  Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

  NCT04477681· Source

• Active, not recruiting

  Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)

  NCT04075981· Phase 3· Source

• Recruiting

  Dat'Aids Prevention

  NCT03795376· Source

• Recruiting

  Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis

  NCT03268668· Source

• Recruiting

  Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures

  NCT05361603· Source

• Recruiting

  Quality of Care in French HIV Infected Patients

  NCT02898987· Source

• Recruiting

  Treatment of Brain AVMs (TOBAS) Study

  NCT02098252· Source

• Recruiting

  UroCCR Database: French Research Network for Kidney Cancer -UroCCR

  NCT03293563· Source

• Active, not recruiting

  Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

  NCT02870907· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• Acute myeloid leukemia3 recruiting
• HIV3 recruiting
• Sarcoma3 recruiting
• Stroke3 recruiting
• Chronic myeloid leukaemia2 recruiting
• Epilepsy2 recruiting
• Lung cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Cervical cancer1 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Gastric and esophageal cancer1 recruiting
• Haemophilia1 recruiting
• Heart failure1 recruiting
• Hepatitis B1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Multiple myeloma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

  NCT06080399· Source

• Completed

  Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

  NCT05232071· Phase 2· Source

• Completed

  Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure

  NCT04993079· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Source

• Completed

  Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing

  NCT04308603· Source

• Completed

  Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

  NCT04559464· Source

• Completed

  Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

  NCT03690115· Phase 2· Source

• Completed

  Register of Patients With haEmophilia A tReated With Afstyla®

  NCT04675541· Source

• Completed

  Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility

  NCT07164924· Source

• Completed

  Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

  NCT03249870· Phase 2· Source

• Completed

  Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

  NCT02896582· Phase 2· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Source